Literature DB >> 15853559

Is clozapine antisuicidal?

Robert W Kerwin1, Anusha A Bolonna.   

Abstract

Suicide accounts for approximately 10% of patient deaths in schizophrenia. The atypical antipsychotic clozapine (Clozaril), successful in treatment-resistant patients with schizophrenia, may have an additional antisuicidal effect. Numerous published reports, including the collaborative International Suicide Prevention Trial, have compared mortality rates between clozapine recipients and patients receiving other forms of antipsychotic treatment and observed a significant reduction in patient risk for suicide with clozapine therapy. Preliminary reports indicate improvements in suicidality in schizophrenia patients treated with other modern atypical antipsychotics, for example olanzapine [Zyprexa], risperidone [Risperdal] and sertindole [Serdolect], but further investigation is required to clarify their role as antisuicidal drugs. It has been estimated that 53 suicides in treatment-resistant patients could have been prevented by clozapine, but the number of lives saved may be significantly higher if clozapine therapy was extended to treatment responders at a high risk for suicide.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15853559     DOI: 10.1586/14737175.4.2.187

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  3 in total

Review 1.  Pharmacological management of atypical antipsychotic-induced weight gain.

Authors:  Trino Baptista; Yamily ElFakih; Euderruh Uzcátegui; Ignacio Sandia; Eduardo Tálamo; Enma Araujo de Baptista; Serge Beaulieu
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 2.  Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment.

Authors:  Leonardo Tondo; Ross J Baldessarini
Journal:  Curr Psychiatry Rep       Date:  2016-09       Impact factor: 5.285

3.  Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia.

Authors:  X Fan; C P C Borba; P Copeland; D Hayden; O Freudenreich; D C Goff; D C Henderson
Journal:  Acta Psychiatr Scand       Date:  2012-09-04       Impact factor: 6.392

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.